1. Home
  2. PMAX vs GRDX Comparison

PMAX vs GRDX Comparison

Compare PMAX & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$0.43

Market Cap

6.4M

Sector

N/A

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.04

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMAX
GRDX
Founded
2019
N/A
Country
Hong Kong
United Kingdom
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMAX
GRDX
Price
$0.43
$2.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
404.1K
114.0K
Earning Date
04-27-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.92
52 Week High
$5.20
$5.30

Technical Indicators

Market Signals
Indicator
PMAX
GRDX
Relative Strength Index (RSI) 18.60 38.44
Support Level $0.31 $2.03
Resistance Level $0.44 $2.56
Average True Range (ATR) 0.12 0.24
MACD -0.06 0.01
Stochastic Oscillator 5.54 9.18

Price Performance

Historical Comparison
PMAX
GRDX

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: